Companies › Tasly Pharmaceuticals
10 active drug programs in 10 registered trials: 6 Phase 3, 4 Phase 1; Cardiovascular, Oncology, Respiratory, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Jitongning tablets | – | Phase 3 | Ankylosing Spondylitis | Dec 2026 |
| T89 capsule Anti-anginal agent | – | Phase 3 | Chronic Stable Angina Pectoris | Dec 2026 |
| Lianxiaxiaopi Granules Traditional herbal medicine | – | Phase 3 | Postprandial Distress Syndrome | Dec 2026 |
| Qishen Yiqi Dripping Pills Traditional Chinese medicine formulation | – | Phase 3 | Heart Failure | Jun 2028 |
| Antiwei Granules Herbal formulation for wind-cold syndrome | – | Phase 3 | Common Cold | – |
| Xiang Ju Ru Pi Ning capsule Traditional Chinese Medicine formulation for treatment of mammary gland hyperplasia | – | Phase 3 | Hyperplasia of Mammary Glands | – |
| B2278 Human umbilical cord mesenchymal stem cells (HucMSCs) with immune regulation, macrophage p | – | Phase 1 | Coronary Artery Bypass Grafting (CABG) | Dec 2026 |
| TSL2109 CDK4/6-DYRK2 dual-target inhibitor | CDK4, CDK6, DYRK2 | Phase 1 | Metastatic Castration-Resistant Prostate Cancer Patients | Dec 2026 |
| B2065 allogeneic adipose-derived mesenchymal stromal cell (AD-MSC) injection | – | Phase 1 | Acute Ischemic Stroke | Dec 2027 |
| P134 cells CD44/CD133 dual-targeting CAR-T cells | CD44, CD133 | Phase 1 | Recurrent Glioblastoma IDH Wildtype | Feb 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06697886 | Antiwei Granules | Phase 3 | Common Cold | Respiratory | Jun 2025 |
| NCT06685978 | Xiang Ju Ru Pi Ning capsule | Phase 3 | Hyperplasia of Mammary Glands | Other | Apr 2026 |
| NCT06000956 | Jitongning tablets | Phase 3 | Ankylosing Spondylitis | Immunology | Dec 2026 |
| NCT03789552 | T89 capsule | Phase 3 | Chronic Stable Angina Pectoris | Cardiovascular | Dec 2026 |
| NCT07514065 | TSL2109 | Phase 1 | Metastatic Castration-Resistant Prostate Cancer Patients | Oncology | Dec 2026 |
| NCT07265349 | B2278 | Phase 1 | Coronary Artery Bypass Grafting (CABG) | Cardiovascular | Dec 2026 |
| NCT06696261 | Lianxiaxiaopi Granules | Phase 3 | Postprandial Distress Syndrome | Gastroenterology | Dec 2026 |
| NCT07371624 | B2065 | Phase 1 | Acute Ischemic Stroke | Neurology | Dec 2027 |
| NCT07318818 | P134 cells | Phase 1 | Recurrent Glioblastoma IDH Wildtype | Oncology | Feb 2028 |
| NCT07687186 | Qishen Yiqi Dripping Pills | Phase 3 | Heart Failure | Cardiovascular | Jun 2028 |
Boryung Pharmaceutical Shandong Suncadia Medicine Sinotau Pharmaceutical Group InSilico Medicine Hong Kong THPharm
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.